A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

A Phase 1, Randomized, Open-label, Parallel-Group, Single-Dose, Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial + Syringe Presentation in Healthy Adults

This is a randomized, open-label, parallel-group, single-dose study comparing the pharmacokinetics of efgartigimod in blood following a single administration of efgartigimod PH20 SC via a prefilled syringe versus a vial + syringe in healthy participants.

Study Overview

• Status: Completed
• Conditions: Bioequivalence
• Intervention / Treatment: Biological: efgartigimod PH20 SC as a prefilled syringe presentation; Biological: efgartigimod PH20 SC as a vial + syringe presentation

• Study Type: Interventional
• Enrollment (Actual): 120
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Tempe, Arizona, United States, 85282
      • Investigator site 0010209
  • Nebraska
    • Lincoln, Nebraska, United States, 68510
      • Investigator site 0010208

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Is at least the local legal age of consent for participation in a clinical study and ≤55 years when signing the ICF
• Is capable of providing signed informed consent, and complying with protocol requirements
• Agrees to use contraceptive measures consistent with local regulations and the following: Women Of Child-Bearing Potential must have a negative serum hCG pregnancy test at screening and a negative urine hCG pregnancy test at baseline before receiving IMP.
• Has a BMI between 18 and 30 kg/m2 , inclusive, and a weight between 50 and 100 kg (inclusive) at screening

Exclusion Criteria:

• Has a known autoimmune disease or any medical condition that, in the investigator's judgment, would interfere with an accurate assessment of clinical symptoms or puts the participant at undue risk
• Has a history of malignancy, unless considered cured by adequate treatment with no evidence of recurrence for ≥3 years before the administration of IMP. Adequately-treated participants with the following cancers can be included at any time: Basal cell or squamous cell skin cancer; Carcinoma in situ of the cervix; Carcinoma in situ of the breast; Incidental histological findings of prostate cancer.
• Has a clinically significant active infection that is not sufficiently resolved in the investigator's opinion.
• Has a positive serum test at screening for active infection with any of the following: HBV indicative of an acute or chronic infection, unless associated with a negative HBsAg or negative HBV DNA test; HCV based on HCV antibody assay unless a negative RNA test is available ; HIV based on test results (regardless of therapy treatment or not).
• Has a clinically significant disease, recent major surgery (within 3 months of screening), or intends to have surgery during the study; or any other medical condition that, in the investigator's opinion, would confound the results of the study or put the participant at undue risk.
• Received a different IMP in another clinical study <12 weeks or 5 half-lives (whichever is longer) before screening.
• Is currently participating in another interventional clinical study. Has a known hypersensitivity to IMP or its excipients.
• Has abdominal skin condition that does not allow for absorption and assessment of local safety of the planned SC injection, as determined by the investigator.
• Has a history of (within 12 months before screening) or current alcohol, drug, or medication abuse, as assessed by the investigator.
• Is pregnant or lactating or intends to become pregnant during the study.
• Previously participated in an efgartigimod clinical study and received at least 1 dose of IMP.
• Is taking concomitant medications (except for oral contraceptives or occasional acetaminophen).
• Has a total IgG of <4 g/L at screening.
• Had a positive COVID-19 test result on day -1 or contact with someone with a known COVID-19 infection within 2 weeks before receiving IMP.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Efgartigimod PH20 SC - prefilled syringe; efgartigimod PH20 SC administered by a prefilled syringe	Biological: efgartigimod PH20 SC as a prefilled syringe presentation; efgartigimod PH20 SC as a prefilled syringe presentation
Active Comparator: Efgartigimod PH20 SC - vial + syringe; efgartigimod PH20 SC administered by a vial + syringe	Biological: efgartigimod PH20 SC as a vial + syringe presentation; efgartigimod PH20 SC as a vial + syringe presentation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary PK parameters (Cmax)	maximum observed plasma concentration	Up to 29 days
Primary PK parameters (AUC0-inf)	area under the concentration-time curve from 0 to infinity	Up to 29 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Total IgG as percent change from baseline over time		up to 57 days
Total IgG as absolute change from baseline over time		up to 57 days
Safety parameters (number of AEs)		up to 85 days
Incidence of ADA against efgartigimod PH20 SC	Incidence of antidrug antibodies against efgartigimod PH20 SC	up to 57 days
Second PK parameters (Tmax)	time to maximum concentration	up to 57 days
Second PK parameters (AUC0-t)	area under the concentration-time curve from 0 to last quantifiable concentration	up to 57 days
Second PK parameters (AUC0-168h)	area under the concentration-time curve from time 0 to168 hours	up to 57 days
Second PK parameters (t1/2)	elimination half-life	up to 57 days
Second PK parameters (Vz/F)	apparent volume of distribution	up to 57 days
Second PK parameters (CL/F)	apparent clearance (total body clearance for extravascular administration divided by the fraction of dose absorbed, calculated using the observed value of the last nonzero concentration)	up to 57 days

Collaborators and Investigators

• Sponsor: argenx

Study record dates

Study Major Dates

• Study Start (Actual): March 13, 2023
• Primary Completion (Actual): May 12, 2023
• Study Completion (Actual): May 12, 2023

Study Registration Dates

• First Submitted: April 5, 2023
• First Submitted That Met QC Criteria: April 5, 2023
• First Posted (Actual): April 18, 2023

Study Record Updates

• Last Update Posted (Actual): October 31, 2023
• Last Update Submitted That Met QC Criteria: October 30, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: ARGX-113-2204

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No